Top Page
Centrica
(LSE:CNA)
Centrica (CNA) vs. iShares MSCI United Kingdom ETF (EWC)
Centrica Business Overview & Revenue Model
Centrica Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.43B | 19.91B | 26.46B | 23.74B | 14.74B | 12.25B |
| Gross Profit | 5.52B | 4.09B | -1.70B | 9.75B | 1.41B | 3.52B |
| EBITDA | 2.01B | 2.42B | 7.08B | 410.00M | 721.00M | 488.00M |
| Net Income | -118.50M | 1.33B | 3.93B | -782.00M | 586.00M | 41.00M |
Balance Sheet | ||||||
| Total Assets | 16.21B | 18.73B | 21.37B | 29.04B | 27.09B | 17.12B |
| Cash, Cash Equivalents and Short-Term Investments | 5.38B | 6.22B | 6.85B | 4.84B | 5.06B | 1.82B |
| Total Debt | 2.93B | 3.51B | 4.10B | 3.96B | 4.58B | 5.29B |
| Total Liabilities | 12.52B | 13.92B | 17.13B | 27.76B | 24.34B | 15.74B |
| Stockholders Equity | 3.30B | 4.42B | 3.88B | 1.02B | 2.37B | 957.00M |
Cash Flow | ||||||
| Free Cash Flow | 276.00M | 733.00M | 2.42B | 943.00M | 1.19B | 778.00M |
| Operating Cash Flow | 633.00M | 1.15B | 2.75B | 1.31B | 1.61B | 1.27B |
| Investing Cash Flow | -166.00M | 493.00M | 115.00M | -566.00M | 2.26B | -354.00M |
| Financing Cash Flow | -989.00M | -1.55B | -1.41B | -917.00M | -938.00M | -280.00M |
Centrica Technical Analysis
Centrica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | £20.92B | 17.46 | 12.29% | 3.38% | -3.11% | -31.10% | |
| ― | £57.13B | 18.68 | 8.35% | 4.08% | -7.42% | 5.84% | |
| ― | £2.51B | -37.48 | -4.44% | 6.42% | 15.42% | -406.43% | |
| ― | $17.65B | 18.10 | 5.60% | 3.62% | 6.62% | 11.55% | |
| ― | £8.15B | -35.66 | -5.95% | 2.74% | -4.82% | -123.58% | |
| ― | £8.28B | 31.29 | 13.05% | 4.30% | 10.04% | 108.60% | |
| ― | £8.42B | 36.69 | 12.73% | 4.35% | 3.78% | 50.18% |
Centrica Corporate Events
Centrica plc has announced the purchase of 1,110,510 of its own ordinary shares at a price of 175.5673 pence per share, as part of its ongoing share buyback program. This transaction, executed through J.P. Morgan Securities plc, is part of the second tranche of the buyback initiative, which began on 22 September 2025. Since the start of this program, Centrica has acquired over 41 million shares, indicating a strategic move to consolidate its share capital and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,972,764 of its own ordinary shares at an average price of 173.1743 pence per share, as part of its ongoing share buyback program. This move, executed through J.P. Morgan Securities, is part of the second tranche of the program initiated on 22 September 2025. The buyback aims to reduce the number of shares in circulation, potentially increasing the value of remaining shares and demonstrating the company’s confidence in its financial health. This strategic financial maneuver could positively impact shareholder value and market perception.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,109,607 of its own ordinary shares at a price of 174.4321 pence per share, as part of its ongoing buyback program. This transaction, executed through J.P. Morgan Securities, is part of a larger initiative that began on 22 September 2025, with Centrica having acquired a total of 36,255,254 shares at a cost of over £61 million. The shares will be held as treasury shares, which could impact the company’s share value and investor perceptions.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,117,023 of its own ordinary shares at an average price of 174.1858 pence per share, as part of its ongoing share buyback program. This transaction is part of the second tranche of the buyback initiative, which began on September 22, 2025, and aims to enhance shareholder value by reducing the number of shares in circulation. Since the start of the program, Centrica has acquired over 35 million shares, reflecting a significant investment in its own equity, which could potentially improve earnings per share and provide a positive signal to the market.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,107,538 of its own ordinary shares at a price of 171.2271 pence per share, as part of the second tranche of its buyback programme. This move, executed through J.P. Morgan Securities plc, is part of a broader strategy to manage its capital structure and return value to shareholders, having already acquired over 34 million shares since September 2025. The acquisition of these shares, which will be held as treasury shares, reflects Centrica’s ongoing efforts to enhance shareholder value and optimize its financial operations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,134,778 of its own ordinary shares at an average price of 172.2517 pence per share, as part of the second tranche of its buyback program initiated on 22 September 2025. This strategic move is part of Centrica’s ongoing efforts to manage its capital structure efficiently, potentially impacting shareholder value and market perception positively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,990,258 of its own ordinary shares at an average price of 168.7173 pence per share, as part of its ongoing share buyback program. This transaction is part of a broader strategy to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing earnings per share. Since the initiation of the buyback program on 22 September 2025, Centrica has acquired a total of 30,786,308 shares, reflecting a significant investment in its own stock. This move is likely to impact the company’s financial structure and could influence market perceptions positively, signaling confidence in its future performance.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the acquisition of ordinary shares under its Share Incentive Plan by executive directors Christopher O’Shea and Russell O’Brien. The transactions involved the purchase of Partnership Shares and Matching Shares, with a total of 111 and 110 shares acquired respectively, at a price of approximately £1.701 per share. This move highlights Centrica’s ongoing commitment to aligning the interests of its management with those of its shareholders, potentially impacting the company’s governance and stakeholder relations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,223,659 of its own ordinary shares at a price of 169.6995 pence per share, which will be held as treasury shares. This transaction is part of the second tranche of the company’s buyback program initiated on September 22, 2025. Since the start of the program, Centrica has acquired a total of 28,796,050 shares at a cost of £48,488,100.42. This move is expected to impact the company’s share capital structure and could potentially influence shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,772,376 of its own ordinary shares at a price of 170.2164 pence per share, as part of the second tranche of its buyback program. This move, executed through J.P. Morgan Securities, is part of a larger strategy to manage its capital structure, with a total of 26,572,391 shares purchased since September 22, 2025, at a cost of £44,714,562.22. The repurchase of shares is likely to impact the company’s financial metrics and shareholder value, indicating a focus on returning value to shareholders and optimizing its capital allocation.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,111,313 of its own ordinary shares at a price of 169.8860 pence per share, as part of its ongoing share buyback program. This transaction, executed through J.P. Morgan Securities, is part of the second tranche of the buyback initiative announced in September 2025. Since the start of this tranche, Centrica has acquired a total of 24,800,015 shares, reflecting a strategic move to consolidate its shareholding and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of over 2 million of its own shares as part of a buyback program, which is a strategy to return value to shareholders and manage capital structure. This move, part of a broader buyback initiative, indicates Centrica’s confidence in its financial health and commitment to enhancing shareholder value, potentially impacting its market positioning positively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,586,292 of its own ordinary shares at an average price of 170.1569 pence per share, as part of the second tranche of its buyback program. This move, executed through J.P. Morgan Securities, is part of a broader strategy to manage capital and potentially enhance shareholder value, reflecting Centrica’s ongoing commitment to optimizing its financial structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc, a leading energy and services company, has announced the purchase of 1,657,571 of its own ordinary shares at a price of 169.5757 pence per share. This transaction is part of the second tranche of the company’s buyback program, which was initiated on September 22, 2025. Since the start of the program, Centrica has acquired a total of 19,049,766 shares, reflecting a strategic move to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of over 2 million of its own shares as part of a buyback program, with the shares to be held in treasury. This move is part of a larger strategy initiated in September 2025, aiming to enhance shareholder value and optimize the company’s capital structure. The buyback program reflects Centrica’s confidence in its financial position and its commitment to returning value to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,442,483 of its ordinary shares at an average price of 168.9356 pence per share, as part of its ongoing share buyback program. This transaction is part of the second tranche of the buyback initiative, which began on 22 September 2025. Since the start of this tranche, Centrica has acquired over 15 million shares, reflecting a strategic move to enhance shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced its total voting rights as of September 30, 2025, with an issued capital comprising over 5.1 billion ordinary shares. After accounting for shares held in treasury, 4.7 billion shares carry voting rights, which stakeholders can use to determine their notification obligations under the Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc, a prominent player in the energy sector, has executed a significant share buyback, purchasing over 2 million of its ordinary shares at an average price of 165.3319 pence per share. This move is part of the company’s ongoing buyback program aimed at consolidating its share capital and potentially enhancing shareholder value. The transaction, facilitated by J.P. Morgan Securities plc, reflects Centrica’s strategic financial management and commitment to optimizing its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the completion of Spirit Energy’s sale of a 46.25% interest in the Cygnus gas field to Ithaca Energy plc for £116 million. This transaction, which includes the transfer of associated decommissioning liabilities, allows Spirit Energy to retain a 15% stake in the gas field. The sale is expected to impact Centrica’s operations by potentially optimizing its asset portfolio and enhancing its financial position, while also influencing its strategic positioning within the energy industry.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of nearly 2 million of its own ordinary shares as part of its ongoing buyback program. This move, executed through J.P. Morgan Securities, is part of a larger strategy to manage the company’s capital structure and potentially enhance shareholder value. The purchase increases Centrica’s treasury shares to nearly 440 million, reflecting a significant investment in its own equity.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,859,339 of its own ordinary shares at a price of 166.9552 pence each, as part of its ongoing share buyback program. This transaction, executed through J.P. Morgan Securities, is part of the second tranche of the buyback initiative, which began on 22 September 2025. Since the start of the program, Centrica has acquired a total of 9,780,267 shares at a cost of £16,378,543.26. The repurchase of shares is intended to be held as treasury shares, potentially impacting the company’s share capital structure and providing value to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,086,560 of its own ordinary shares at a price of 166.1757 pence per share, as part of its ongoing buyback program. This transaction is part of the second tranche of the program, which began on 22 September 2025. Since the start of this tranche, Centrica has acquired a total of 7,920,928 shares, costing £13,274,280.11. The repurchased shares will be held as treasury shares, potentially impacting the company’s share value and providing flexibility in capital management.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its directors, Philippe Boisseau and Sue Whalley, have acquired ordinary shares in the company as per their Share Purchase Agreements. These transactions, conducted on the London Stock Exchange, are part of the company’s ongoing efforts to align management interests with shareholder value, potentially impacting investor confidence and company governance.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,952,587 of its own ordinary shares at an average price of 167.7898 pence per share, as part of its ongoing share buyback program. This transaction, executed through J.P. Morgan Securities, is part of the second tranche of the buyback initiative, which aims to enhance shareholder value by reducing the number of shares in circulation. Since the start of this tranche, Centrica has acquired a total of 5,834,368 shares, reflecting a strategic move to optimize capital structure and potentially increase earnings per share.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,887,411 of its own ordinary shares at a price of 168.2100 pence per share, as part of the second tranche of its buyback program initiated on 22 September 2025. This transaction, executed through J.P. Morgan Securities, brings the total shares repurchased since the program’s announcement to 3,881,781, costing the company £6,530,682.60. The repurchased shares will be held as treasury shares, potentially impacting the company’s share value and offering flexibility in managing its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,994,370 of its own ordinary shares at an average price of 168.2671 pence per share, as part of its ongoing share buyback program. This move, executed through J.P. Morgan Securities, is aimed at consolidating its treasury shares, which now total 430,311,372, reflecting the company’s strategic financial management and potential impact on shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the cancellation of 78,500,000 ordinary shares held in treasury, aligning with its policy to keep treasury shares below 10% of total issued share capital. This cancellation adjusts the number of treasury shares to 428,317,002, representing 8.27% of the total issued share capital, potentially impacting the company’s share value and stakeholder interests.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the completion of the first tranche of its 2025 share buyback program, purchasing 1,365,700 ordinary shares at an average price of 167.4700 pence per share. This marks the conclusion of the first £250 million segment of the program, with plans to repurchase a total of £500 million worth of shares. The buyback is part of Centrica’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has appointed Frank Mastiaux as a Non-Executive Director, effective from 22 September 2025. Mastiaux brings extensive experience from the energy sector, having previously led significant transformations at major European utilities, including EnBW. His expertise in both traditional and renewable energy systems is expected to support Centrica’s strategic goals in sustainability and innovation.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the commencement of the second and final £250 million tranche of its £500 million share buyback programme extension, bringing the total programme to £2.0 billion. This tranche, conducted in partnership with J.P. Morgan Securities, aims to reduce the company’s capital by repurchasing up to 3% of its issued share capital. The repurchased shares may be cancelled, held in treasury, or used for employee share schemes, with the process adhering to UK market regulations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,236,791 of its own ordinary shares at an average price of 166.4100 pence per share, as part of its 2025 buyback programme. This move is part of a broader strategy to enhance shareholder value and manage capital efficiently, reflecting the company’s commitment to returning capital to shareholders and potentially impacting its share price positively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,900,000 of its own ordinary shares at an average price of 169.1400 pence per share, as part of its ongoing 2025 buyback programme. This move is part of the first tranche of the programme’s extension, aiming to enhance shareholder value by reducing the number of shares in circulation, which could potentially increase earnings per share and improve market perception.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £210.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,100,000 of its own ordinary shares at a price of 164.0000 pence per share, as part of the first tranche of its 2025 buyback programme. This move is part of a larger strategy to manage its share capital and enhance shareholder value, with the purchased shares being held as treasury shares. Since June 2025, Centrica has acquired a total of 149,888,141 ordinary shares, reflecting a significant investment in its own stock, which could have implications for its market positioning and shareholder confidence.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £1.90 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a significant share buyback, purchasing over 1.26 million shares at an average price of 164.1 pence each, as part of its 2025 buyback programme. This move, facilitated through Goldman Sachs International, is part of a broader strategy to enhance shareholder value and optimize the company’s capital structure, reflecting its strong financial position and commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £1.90 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 5,699,577 of its own ordinary shares at a price of 160.7600 pence per share, as part of its 2025 buyback programme. This move is part of the company’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, increasing Centrica’s total treasury shares to 499,000,310. This buyback is expected to enhance shareholder value and reflects Centrica’s confidence in its financial position.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £1.90 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 5,207,728 of its own ordinary shares at a price of 156.4000 pence per share, which will be held as treasury shares. This transaction is part of the first tranche of the company’s 2025 buyback programme, executed through Goldman Sachs International. Since June 2025, Centrica has acquired a total of 141,825,273 shares at a cost of over £227 million, reflecting its strategy to enhance shareholder value and manage its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 5,207,728 of its own ordinary shares at a price of 156.4000 pence per share, as part of its ongoing 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of the first tranche of the programme’s extension announced earlier this year. The acquisition of these shares, which will be held as treasury shares, reflects Centrica’s strategic focus on optimizing its capital structure and returning value to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its Share Incentive Plan administrators, Equiniti Limited, have acquired ordinary shares on behalf of its executive directors, Christopher O’Shea and Russell O’Brien. The transactions involve the acquisition of Partnership Shares and Matching Shares, with a total of 117 shares for O’Shea and 118 shares for O’Brien, conducted on the London Stock Exchange and outside a trading venue. This move highlights the company’s commitment to aligning the interests of its executives with those of its shareholders, potentially impacting stakeholder confidence and executive engagement.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 4,089,458 of its own ordinary shares at a price of 155.9600 pence per share, which will be held as treasury shares. This transaction is part of the first tranche of the company’s 2025 buyback programme, which was extended earlier in the year. Since June 2025, Centrica has acquired a total of 136,617,545 shares at a cost of £219,591,838.72. The buyback programme is a strategic move to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,719,058 of its own ordinary shares at a price of 154.4200 pence per share, as part of the first tranche of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of Centrica’s ongoing strategy to manage its capital structure and return value to shareholders, further solidifying its position in the energy market.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,426,168 of its own ordinary shares at a price of 154.7700 pence each, as part of the first tranche of its extended 2025 buyback program. This move, executed through Goldman Sachs International, is part of Centrica’s strategy to manage its capital structure and return value to shareholders, reflecting confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,762,183 ordinary shares at a price of 154.9100 pence per share, as part of the first tranche of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of a broader strategy to manage its capital structure and return value to shareholders. Following this transaction, Centrica holds 477,079,856 shares in treasury, with a total of 4,780,527,358 shares in issue. The buyback programme reflects Centrica’s commitment to enhancing shareholder value and optimizing its financial resources.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,229,051 of its ordinary shares at an average price of 155.4000 pence per share, as part of its ongoing 2025 buyback program. This transaction, executed through Goldman Sachs International, is part of a broader strategy to manage its capital structure and enhance shareholder value. Following this purchase, Centrica holds 474,343,314 shares in treasury, with 4,783,263,900 shares remaining in issue. This move may impact the company’s financial metrics and shareholder returns, signaling confidence in its financial health and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,340,508 of its own ordinary shares at a price of 155.2600 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing effort to manage its share capital and enhance shareholder value by holding the purchased shares as treasury shares.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,925,990 of its own ordinary shares at a price of 156.4800 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing strategy to manage its capital structure and enhance shareholder value, with a total of 116,051,119 shares purchased since June 2025 at a cost of £187,684,954.79. The buyback is expected to impact the company’s financial positioning by reducing the number of shares in circulation, potentially increasing earnings per share and providing a return of capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,370,603 ordinary shares at a price of 161.0700 pence per share, as part of the first tranche of its 2025 buyback programme. This move, executed through Goldman Sachs International, reflects Centrica’s ongoing strategy to manage its capital structure and return value to shareholders, potentially enhancing its market position and shareholder confidence.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has announced the extension of the operational life of two UK nuclear power stations, Heysham 1 and Hartlepool, until March 2028, enhancing energy security for Britain. This extension will contribute an additional 3 TWh to Centrica’s electricity generation volumes and aligns with the UK’s ambition for a clean energy supply. The company is also investing in the Sizewell C nuclear project, further demonstrating its commitment to a diversified, low-carbon energy system and supporting the UK’s long-term decarbonization efforts.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced its total voting rights as of 31 August 2025, with an issued capital comprising over 5.2 billion ordinary shares. Out of these, approximately 4.8 billion shares have voting rights, which shareholders can use to determine their notification obligations under the Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 737,549 of its own ordinary shares at a price of 161.0600 pence per share, which will be held as treasury shares. This transaction is part of the first tranche of the company’s 2025 buyback programme, reflecting Centrica’s ongoing efforts to manage its capital structure and enhance shareholder value. The buyback programme, executed through Goldman Sachs International, highlights Centrica’s strategic focus on optimizing its financial operations and maintaining a robust market position.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 737,549 of its own ordinary shares at an average price of 161.0600 pence per share, as part of the first tranche of its 2025 buyback program. This move is part of a broader strategy to enhance shareholder value, with the company having acquired over 109 million shares since June 2025. The shares will be held as treasury shares, reflecting Centrica’s ongoing commitment to managing its capital structure effectively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,389,926 of its own ordinary shares at a price of 161.6800 pence per share, as part of its 2025 buyback program. This move, executed through Goldman Sachs International, is part of an ongoing effort to manage share capital and enhance shareholder value, with significant implications for the company’s financial strategy and market positioning.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,153,606 of its own ordinary shares at a price of 163.5700 pence per share, as part of the first tranche of its 2025 buyback programme. This move is part of an ongoing effort to manage its capital structure and enhance shareholder value, with the shares being held as treasury shares. Since June 2025, Centrica has acquired over 107 million shares, reflecting its strategic commitment to returning value to shareholders and maintaining a robust financial position.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 999,633 of its own ordinary shares at a price of 163.6200 pence per share, as part of the first tranche of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with Centrica having purchased over 105 million shares since June 2025.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that Philippe Boisseau, a Non-Executive Director, acquired ordinary shares of the company as part of a Share Purchase Agreement. This transaction, conducted on the London Stock Exchange, reflects ongoing engagement and investment by the company’s leadership, potentially reinforcing stakeholder confidence in Centrica’s strategic direction.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,348,730 of its own ordinary shares at a price of 166.4800 pence per share, which will be held as treasury shares. This transaction is part of the first tranche of the company’s 2025 buyback programme, reflecting Centrica’s ongoing efforts to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 559,344 of its own ordinary shares at a price of 165.0900 pence per share, as part of its 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, reflecting Centrica’s ongoing commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,841,244 of its own ordinary shares at a price of 163.1500 pence per share, as part of the first tranche of its 2025 buyback program. This move is in line with the company’s strategy to manage its capital structure and return value to shareholders, impacting its treasury holdings and overall share issuance.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,984,685 of its own ordinary shares at a price of 163.6000 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, reflects Centrica’s ongoing strategy to manage its capital structure and enhance shareholder value, holding a total of 452,512,257 shares in treasury following the purchase.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,511,711 of its own ordinary shares at a price of 163.7600 pence per share, as part of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of the first tranche of the buyback extension, indicating Centrica’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 894,768 of its own ordinary shares at a price of 168.3500 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing effort to manage the company’s capital structure and return value to shareholders. Following this purchase, Centrica holds 448,015,861 shares in treasury, with 4,809,591,353 shares remaining in issue. This move is expected to impact the company’s share value and market perception positively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,197,446 of its own ordinary shares at a price of 166.7100 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of the first tranche of the programme’s extension, which began on 20 February 2025. Since 16 June 2025, Centrica has acquired a total of 95,333,330 shares, costing £154,090,612.95, excluding additional costs. Following this purchase, Centrica holds 447,246,730 shares in treasury, with 4,810,360,484 shares in issue. This buyback effort is expected to enhance shareholder value and optimize the company’s capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback transaction, purchasing 1,254,336 ordinary shares at a price of 162.1700 pence per share, as part of its 2025 buyback programme. This move, facilitated through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the acquisition of the Isle of Grain liquified natural gas terminal in partnership with Energy Capital Partners for £1.5 billion. This strategic investment aligns with Centrica’s focus on energy security and transition, providing critical LNG import/export and storage capacity. The terminal is expected to deliver strong financial returns and support Centrica’s medium-term financial targets, with significant contracted capacity until 2045. The acquisition underscores Centrica’s commitment to energy infrastructure and its role in the UK’s energy transition.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,798,286 of its own ordinary shares at a price of 163.1300 pence per share, as part of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of a broader strategy to manage its capital structure and return value to shareholders. Following this transaction, Centrica holds 442,794,948 ordinary shares in treasury, with 4,814,812,266 shares in issue. This buyback is expected to positively impact the company’s stock value and demonstrate its commitment to enhancing shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its executive directors, Christopher O’Shea and Russell O’Brien, have acquired ordinary shares under the company’s Share Incentive Plan. This transaction, facilitated by Equiniti Share Plan Trustees Limited, involved the acquisition of both Partnership Shares and Matching Shares, highlighting Centrica’s ongoing efforts to align executive interests with shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,060,640 of its own ordinary shares at a price of 164.4100 pence per share, as part of its 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is a continuation of the company’s strategy to enhance shareholder value, with a total of 89,083,262 shares purchased since June 2025, costing approximately £143.8 million.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 943,073 of its own ordinary shares at a price of 166.7000 pence per share, as part of the first tranche of its 2025 buyback programme. This acquisition, executed through Goldman Sachs International, reflects Centrica’s ongoing strategy to manage its capital structure and return value to shareholders, with a total of 87,022,622 shares purchased since June 2025.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,265,301 of its own ordinary shares at a price of 166.4600 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing effort to manage the company’s capital structure and enhance shareholder value. Following this purchase, Centrica holds 438,189,572 ordinary shares in treasury, with a total of 4,819,417,642 shares in issue. This strategic move is likely to impact the company’s market positioning and could have implications for its stakeholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,559,457 ordinary shares at a price of 167.9500 pence per share, as part of the first tranche of its 2025 buyback programme. This move is part of an ongoing effort to manage its capital structure and return value to shareholders, with a total of 84,814,248 shares purchased since June 2025 at a cost of over £136 million. The shares will be held in treasury, and the transaction was executed through Goldman Sachs International.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback transaction, purchasing 2,473,833 of its own ordinary shares at a price of 164.4000 pence per share, as part of its 2025 buyback programme. This move, facilitated by Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, reflecting Centrica’s ongoing commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,009,156 of its own ordinary shares at a price of 165.8100 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of a larger effort that has seen Centrica acquire over 80 million shares since June 2025, reflecting the company’s strategic focus on enhancing shareholder value and optimizing its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,500,000 of its own ordinary shares at a price of 164.9300 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, increases the total number of shares held in treasury to 430,881,825. The buyback initiative, which began in June 2025, has seen Centrica acquire over 78 million shares, reflecting the company’s strategy to enhance shareholder value and optimize its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced its total voting rights as of July 31, 2025, with an issued capital comprising over 5.2 billion ordinary shares. Out of these, approximately 4.8 billion shares carry voting rights, which shareholders can use to determine their notification obligations under the Disclosure Guidance and Transparency Rules. This announcement is crucial for stakeholders to understand their voting power and any changes in their interests in the company.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £1.85 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,259,655 of its own ordinary shares at an average price of 163.6100 pence per share, as part of its 2025 buyback programme. This move is part of the first tranche of the programme’s extension, aimed at consolidating its market position and potentially enhancing shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,259,655 of its own ordinary shares at a price of 163.6100 pence per share, as part of its 2025 buyback programme. This move, executed through Goldman Sachs International, indicates Centrica’s ongoing efforts to manage its share capital effectively, potentially enhancing shareholder value and reflecting confidence in its financial health.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the cancellation of 78,500,000 ordinary shares held in treasury, aligning with its policy to keep treasury shares below 10% of total issued share capital. This move reduces the number of treasury shares to 428,323,701, representing 8.15% of the total issued share capital, potentially impacting the company’s market positioning by enhancing shareholder value and optimizing capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 981,140 of its own ordinary shares at a price of 161.1600 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing effort to manage its share capital and potentially enhance shareholder value. Following this purchase, Centrica holds 506,823,701 shares in treasury, with a total of 4,829,283,513 shares in issue.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,784,041 of its own ordinary shares as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of a broader strategy to manage share capital, with the company having purchased over 75 million shares since June 2025. The move is expected to impact Centrica’s financial structure by increasing treasury shares and potentially influencing shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 3,839,569 of its ordinary shares at a price of 160.2300 pence per share, as part of its ongoing 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of a larger initiative that has seen the company repurchase over 73 million shares since June 2025. The move is expected to enhance shareholder value and reflects Centrica’s strategic focus on optimizing its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the re-appointment of Deloitte LLP as its external auditor following a competitive audit tender process. Deloitte will serve as the external auditor for the financial years ending December 2025, 2026, and 2027, subject to shareholder approval at the 2026 and 2027 AGMs. This decision, endorsed by Centrica’s Board, reflects the company’s commitment to maintaining rigorous financial oversight.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,139,860 of its own ordinary shares at a price of 161.2800 pence per share, as part of its 2025 buyback program. This transaction, executed through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its Non-Executive Director, Philippe Boisseau, has acquired ordinary shares in the company, as part of a Share Purchase Agreement. This transaction, conducted on the London Stock Exchange, reflects the director’s investment in the company, potentially signaling confidence in Centrica’s market position and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced a change in its paying agents for several of its outstanding notes. The company will replace HSBC Bank plc and HSBC Continental Europe with Citibank, N.A., London Branch and Citibank Europe plc as the new Principal Paying Agent and Paying Agent, respectively, effective from 29 August 2025. This change is part of a supplemental agency agreement that includes minor amendments to commercial terms due to legislative updates, potentially impacting the company’s financial operations and stakeholder relations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,940,605 of its own ordinary shares at a price of 160.7900 pence per share, as part of the first tranche of its 2025 buyback programme. This move is part of a broader strategy to manage its capital structure and return value to shareholders, with the purchased shares being held as treasury shares.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,940,605 of its own ordinary shares at a price of 160.7900 pence per share on 24 July 2025. This transaction is part of the first tranche of the company’s 2025 buyback program, which was extended earlier this year. The shares will be held as treasury shares, contributing to a total of 499,271,759 ordinary shares in treasury. This buyback initiative reflects Centrica’s strategic financial management and could potentially enhance shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,870,179 of its own ordinary shares at a price of 159.9000 pence per share, as part of its 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of an ongoing effort to manage its capital structure, with a total of 65,326,932 shares purchased since June 2025. The acquired shares will be held as treasury shares, impacting the company’s share capital and potentially influencing shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced its interim results for the first half of 2025, highlighting a proposed interim dividend of 1.83p per share, to be paid on 30 October 2025. The company assures shareholders of sufficient distributable reserves to support these dividend payments, reflecting a stable financial position. This announcement underscores Centrica’s commitment to returning profits to shareholders and maintaining investor confidence.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.